Thyroid Cancer Clinical Trial
Official title:
The Role of Sentinel Lymph Node Biopsy (SLNB) In the Management of Differentiated Thyroid Cancer
Detection of lymph nodes starting to be involved by cancer spreading from the thyroid gland
during operation is useful. It saves the patient from having a second operation to remove
these nodes later on when they become obvious. The problem is that there are many lymph
nodes around the gland. The theory is that only one node will get the first spill of the
tumour cells.
In this study the investigators are trying to use an inert colored material to inject into
the tumour. This should run in the same path as the tumour cells and should therefore stain
the one lymph node that will be affected first should the tumour spread.
The stained lymph node is excised and examined instantaneously for tumour affection. If it
is found to be affected by the tumour, then the operation is extended to include removal of
all its fellow lymph nodes. If it is found to be free from the tumour, then this patient
does not have tumour spread.
The study includes 45 consecutive patients diagnosed as differentiated thyroid cancer by
clinical examination and/or fine needle aspiration cytology (FNAC).
Exclusion criteria are: previous neck surgery, pregnancy and known hypersensitivity to the
dye used.
An informed consent was obtained from all the patients. Peroperative workup includes history
taking, clinical examination, relevant laboratory investigations including thyroid hormone
assay, ultrasonography of the neck with special emphasis on the thyroid focal lesion and
cervical lymph nodes. FNAC was attempted in all patients.
All patients were then subjected to operation:
A systematized surgical approach was adopted for the purpose of the study: this started by
collar incision, development of sub-platysmal skin flaps and separation of strap muscles in
the midline. This was followed by exposure of the thyroid gland; identification of the
thyroid tumour; injection of the dye into the tumour; waiting for the dye to reach the lymph
nodes; identifying the stained node; labeling it as the sentinel node (SLN); performing
total thyroidectomy and bilateral central neck dissection.
The resected specimen was fixed by formaldehyde, stained with hematoxylin and eosin and
examined with light microscopy.
If the SLN was found to be free of malignant deposits, it was further examined by
immunohistochemical staining.
Statistical analysis: Descriptive statistics were used to analyze demographic data.
Sensitivity, specificity and predictive value of the SLN were calculated.
The histopathological report of the excised specimen was considered the criterion standard.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05774535 -
Prospective, Observational Study on the Carotid Intima-media Thickness in Patients Undergoing Thyroid Surgery
|
||
Withdrawn |
NCT04224792 -
Effects of Exercise Training on Fatigue in Thyroid Cancer Survivors
|
N/A | |
Completed |
NCT01728623 -
A Study of E7080 in Subjects With Advanced Thyroid Cancer
|
Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT02911155 -
Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists
|
||
Recruiting |
NCT05025046 -
NGS-based Thyroscan Genomic Classifier in the Diagnosis of Thyroid Nodules
|
||
Not yet recruiting |
NCT03978351 -
The Role of Midkine in Diagnosis of Thyroid Cancer
|
||
Completed |
NCT02658513 -
Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer
|
||
Terminated |
NCT02628535 -
Safety Study of MGD009 in B7-H3-expressing Tumors
|
Phase 1 | |
Completed |
NCT02375451 -
Effect of Childhood Radioiodine Therapy on Salivary Function
|
N/A | |
Withdrawn |
NCT01994200 -
Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) for Thyroid Cancer Patients
|
Phase 1/Phase 2 | |
Terminated |
NCT01403324 -
Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer
|
N/A | |
Completed |
NCT00970359 -
Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244
|
N/A | |
Completed |
NCT00439478 -
Dental Safety Profile of High-Dose Radioiodine Therapy
|
Phase 4 | |
Completed |
NCT00223158 -
Evaluation Study of L-T3 Utility in the Follow-up of Patients With Thyroid Cancer
|
N/A | |
Active, not recruiting |
NCT04544111 -
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
|
Phase 2 | |
Completed |
NCT04876287 -
Salivary dysfuncTion After Radioiodine Treatment
|
||
Recruiting |
NCT06073223 -
Intervention to Decrease Overtreatment of Patients With Low-risk Thyroid Cancer
|
N/A | |
Recruiting |
NCT06037174 -
Comparison of Quality of Life in Patients With Differentiated Thyroid Carcinoma Undergoing Different Surgery
|
||
Recruiting |
NCT04952493 -
Anlotinib or Penpulimab in Combination With RAI for DTC
|
Phase 2 |